• 24014 Citations
  • 81 h-Index
1975 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Peter J Houghton is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium

Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., McGeehan, G. M., Erickson, S. W., Smith, M. A. & Houghton, P. J., Jan 1 2020, (Accepted/In press) In : Pediatric Blood and Cancer.

Research output: Contribution to journalArticle

  • Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

    Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A. & Gorlick, R., Jun 1 2020, In : Pediatric Blood and Cancer. 67, 6, e28222.

    Research output: Contribution to journalArticle

  • Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

    Kolb, E. A., Houghton, P. J., Kurmasheva, R. T., Mosse, Y. P., Maris, J. M., Erickson, S. W., Guo, Y., Teicher, B. A., Smith, M. A. & Gorlick, R., May 1 2020, In : Pediatric Blood and Cancer. 67, 5, e28098.

    Research output: Contribution to journalArticle

  • Prospective use of the single-mouse experimental design for the evaluation of PLX038A

    Ghilu, S., Li, Q., Fontaine, S. D., Santi, D. V., Kurmasheva, R. T., Zheng, S. & Houghton, P. J., Feb 1 2020, In : Cancer chemotherapy and pharmacology. 85, 2, p. 251-263 13 p.

    Research output: Contribution to journalArticle

  • A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)

    Mosse, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D., Barkauskas, D. A., Krailo, M., Voss, S. D., Berg, S. L., Blaney, S. M. & Weigel, B. J., Jun 1 2019, In : Clinical Cancer Research. 25, 11, p. 3229-3238 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations

    Press / Media

    2019 election results

    Peter J Houghton

    2/27/202/28/20

    2 items of Media coverage

    Press/Media: Press / Media

    Neuroscientist Susan Amara Named AAAS President-Elect

    Peter J Houghton

    1/28/20

    1 item of Media coverage

    Press/Media: Press / Media

    UF researchers discover breakthrough anticancer drug

    Robert A Hromas & Peter J Houghton

    1/2/20

    1 item of Media coverage

    Press/Media: Press / Media

    Leukemia, lymphoma squarely in sights of new class of drugs

    Robert A Hromas & Peter J Houghton

    12/6/1912/9/19

    6 items of Media coverage

    Press/Media: Press / Media

    Team Develop Drugs To Fight Leukemia and Lymphoma

    Robert A Hromas & Peter J Houghton

    12/9/19

    1 item of Media coverage

    Press/Media: Press / Media